PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US patent 12030959. This proceeding, IPR2026-00260, is currently pending, meaning no claims have been invalidated or sustained by the PTAB yet. Therefore, the patent's defensive posture for a defendant remains largely unhardened, with an active challenge in its very early stages.

IPR2026-00260 — Amneal Pharmaceuticals, Inc. et al. v. Genentech Inc.

• Type: Inter Partes Review
• Filed: 2026-05-26
• Status: Pending. The petition has been filed, but no institution decision has been made by the PTAB.
• Judge panel: Not yet publicly assigned or available, as the proceeding is newly filed.
• Petition grounds: Details regarding specific claims challenged, prior art, and statutory bases (§ 102 / § 103 / § 112) are not yet publicly available in the initial status.
• Institution decision: Not yet issued. The PTAB typically has three months from the patent owner's preliminary response (or waiver thereof) to issue an institution decision.
• Final Written Decision (if issued): Not yet issued.
• Settlement / termination: Not yet applicable.
• Appeal: Not yet applicable.
• Defensive value: As this IPR was filed on the current date, its defensive value is limited at this stage. It signals that Amneal Pharmaceuticals, Inc. and potentially other parties are challenging the patent, but the merits of their challenge have not yet been assessed by the PTAB. A defendant facing assertion of this patent should monitor this IPR closely for institution and subsequent developments.

Strategic summary

As of May 26, 2026, IPR2026-00260 is the only known AIA trial proceeding against US patent 12030959, and it has just been filed. Consequently, all claims of US12030959 are currently UNTESTED by the PTAB, as no institution decision has been rendered. There are no canceled or sustained claims at this time.

Regarding the estoppel landscape, since the IPR is newly filed, no estoppel under § 315(e)(2) has yet been created. This means that if the petition is instituted, Amneal Pharmaceuticals, Inc. (and any privies) would be barred from raising any grounds they raised or reasonably could have raised in the IPR if a Final Written Decision is issued. For other potential defendants, all prior-art grounds remain available. There is no discernible pattern yet, as this is the first recorded PTAB activity for this patent, and it appears to be a direct challenge by a pharmaceutical company.

Recommended next steps

If you are a defendant facing assertion of US patent 12030959, the primary next step is to closely monitor IPR2026-00260. Key milestones to watch for include:

• Patent Owner's Preliminary Response: This will provide insight into the patent owner's arguments against institution.
• Institution Decision: The PTAB's decision on whether to institute the IPR will be critical. If instituted, it indicates the PTAB believes there's a reasonable likelihood that at least one challenged claim is unpatentable.
• Statutory Deadline: The PTAB generally has one year from the date of institution to issue a Final Written Decision. This timeline will provide an estimated date for a potential outcome.

As the proceeding is in its earliest stages, there is no Final Written Decision to link to yet.